Sensei Biotherapeutics (NASDAQ:FTH) CFO Buys 831 Shares of Stock

by · The Cerbat Gem

Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) CFO Brian Stephenson purchased 831 shares of Sensei Biotherapeutics stock in a transaction dated Monday, June 29th. The stock was bought at an average price of $23.34 per share, with a total value of $19,395.54. Following the acquisition, the chief financial officer directly owned 33,885 shares of the company’s stock, valued at approximately $790,875.90. This trade represents a 2.51% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Sensei Biotherapeutics Trading Down 5.4%

Sensei Biotherapeutics stock traded down $1.34 during mid-day trading on Wednesday, reaching $23.66. The company’s stock had a trading volume of 114,325 shares, compared to its average volume of 89,623. The company has a market cap of $31.70 million, a P/E ratio of -0.17 and a beta of -0.26. Sensei Biotherapeutics, Inc. has a 12 month low of $6.32 and a 12 month high of $36.76.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Weiss Ratings started coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating for the company. BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. HC Wainwright initiated coverage on shares of Sensei Biotherapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $60.00 price target on the stock. Finally, Robert W. Baird assumed coverage on Sensei Biotherapeutics in a research report on Friday, June 26th. They set an “outperform” rating and a $57.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Sensei Biotherapeutics presently has an average rating of “Buy” and a consensus price target of $58.50.

Get Our Latest Analysis on FTH

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.

Featured Stories